Antithrombotic Treatment After Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Procedures: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.20344/amp.22905Keywords:
Anticoagulants/administration & dosage, Bioprosthesis, Cardiac Catheterization, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Thrombosis/prevention & controlAbstract
Introduction: While antithrombotic therapy following transcatheter valve implantation has been extensively studied in various clinical trials, there remains a notable gap in evidence regarding the optimal approach following valve-in-valve (ViV), valve-in-ring (ViR) and valve-in-mitral annular calcification (ViMAC) procedures, warranting further assessment. This gap is particularly concerning due to the apparent increased risk of thrombosis associated with ViV interventions. The aim of this systematic review was to explore the potential benefits of anticoagulation in ViV, ViR, and ViMAC procedures.
Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, as well as the grey literature, for observational and interventional studies published until December 2023. Trials were included if a comparative analysis between the two antithrombotic strategies was feasible and excluded if patients under 18 years old were analysed. The primary efficacy endpoints were incidence of clinical and total valve thrombosis (VT), major bleeding was the sole safety primary endpoint. Additional analyses were performed regarding valves in the mitral position and valve type. The risk of bias was evaluated using the Newcastle-Ottawa scale. Data was assessed using the Review Manager 5.4 software.
Results: A total of five observational and one case series were included (n = 614 on anticoagulation and n = 468 on antiplatelets), comprising a total of 1082 participants. Clinical VT rates were 4.2% for all procedures, and patients on anticoagulants were associated with a a lower risk of clinical VT (1.1% vs 8.3%; OR: 0.18; 95% CI: 0.07 - 0.42, I2: 0%) and total VT (1.3% vs 8.5%; OR: 0.16; 95% CI: 0.07 - 0.37, I2: 0%). Regarding bleeding events, the existing literature did not provide adequate information to enable a thorough analysis.
Conclusion: Our study suggests a potential benefit of anticoagulation regimens to decrease the high rates of VT following valve-in-valve, valve-in-ring and valve-in-mitral annular calcification procedures. However, the lack of randomized controlled trials and data on bleeding and mortality emphasises the necessity for further research.
Downloads
References
Kiyose AT, Suzumura EA, Laranjeira L, Buehler AM, Santo JA, Berwanger O, et al. Comparison of biological and mechanical prostheses for heart valve surgery: a systematic review of randomized controlled trials. Arq Bras Cardiol. 2019;112:292-301. DOI: https://doi.org/10.5935/abc.20180272
Bartus K, Sadowski J, Litwinowicz R, Filip G, Jasinski M, Deja M, et al. Changing trends in aortic valve procedures over the past ten years—from mechanical prosthesis via stented bioprosthesis to TAVI procedures—analysis of 50,846 aortic valve cases based on a Polish National Cardiac Surgery Database. J Thorac Dis. 2019;11:2340-9. DOI: https://doi.org/10.21037/jtd.2019.06.04
Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodés-Cabau J. Aortic bioprosthetic valve durability. J Am Coll Cardiol. 2017;70:1013-28. DOI: https://doi.org/10.1016/j.jacc.2017.07.715
Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J. 2019;40:441-51. DOI: https://doi.org/10.1093/eurheartj/ehy590
Bruno F, Elia E, D’Ascenzo F, Marengo G, Deharo P, Kaneko T, et al. Valve-in-valve transcatheter aortic valve replacement or re-surgical aortic valve replacement in degenerated bioprostheses: a systematic review and meta-analysis of short and midterm results. Catheter Cardiovasc Interv. 2022;100:122-30. DOI: https://doi.org/10.1002/ccd.30219
Kilic A, Acker MA, Gleason TG, Sultan I, Vemulapalli S, Thibault D, et al. Clinical outcomes of mitral valve reoperations in the United States: an analysis of the society of thoracic surgeons national database. Ann Thorac Surg. 2019;107:754-9. DOI: https://doi.org/10.1016/j.athoracsur.2018.08.083
Xu X, Liu H, Gu J, Li M, Shao Y. Valve-in-valve/valve-in-ring transcatheter mitral valve implantation vs. redo surgical mitral valve replacement for patients with failed bioprosthetic valves or annuloplasty rings: a systematic review and meta-analysis. Heliyon. 2023;9:e16078. DOI: https://doi.org/10.1016/j.heliyon.2023.e16078
Sá MP, Eynde J Van den, Simonato M, Cavalcanti LR, Doulamis IP, Weixler V, et al. Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement. JACC Cardiovasc Interv. 2021;14:211-20. DOI: https://doi.org/10.1016/j.jcin.2020.10.020
Ahmad D, Yousef S, Kliner D, Brown JA, Serna-Gallegos D, Toma C, et al. Outcomes of valve-in-valve transcatheter aortic valve replacement. Am J Cardiol. 2024;215:1-7. DOI: https://doi.org/10.1016/j.amjcard.2023.12.061
Collet JP, Belle EV, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43:2783-97. DOI: https://doi.org/10.1093/eurheartj/ehac408
Dangas GD, Tijssen JG, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120-9. DOI: https://doi.org/10.1056/NEJMoa1911425
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.
Mehilli J, Giannini C. Transcatheter valve-in-valve implantation for failed surgical bioprostheses – some answers and many unanswered questions. EuroIntervention. 2020;16:529-31. DOI: https://doi.org/10.4244/EIJV16I7A97
Rheude T, Pellegrini C, Cassese S, Wiebe J, Wagner S, Trenkwalder T, et al. Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves. EuroIntervention. 2020;15:1233-9. DOI: https://doi.org/10.4244/EIJ-D-19-00710
Aktuerk D, Mirsadraee S, Quarto C, Davies S, Duncan A. Leaflet thrombosis after valve-in-valve transcatheter aortic valve implantation: a case series. Eur Heart J Case Rep. 2020;4:1-6. DOI: https://doi.org/10.1093/ehjcr/ytaa221
Notaristefano F, Reccia MR, Notaristefano S, Annunziata R, Sclafani R, Ambrosio G, et al. Bailout surgical explantation of a transcatheter valve-in-valve for subacute thrombosis: when there is no time for anticoagulation. Cardiovasc Revasc Med. 2018;19:536-9. DOI: https://doi.org/10.1016/j.carrev.2017.12.005
Chu J, Nath N, Attanasio S. Thrombolysis for cardiogenic shock secondary to aortic bioprosthetic valve-in-valve thrombosis. Cureus. 2022;14:e33141. DOI: https://doi.org/10.7759/cureus.33141
Rosseel L, Backer OD, Søndergaard L. Clinical valve thrombosis and subclinical leaflet thrombosis following transcatheter aortic valve replacement: is there a need for a patient-tailored antithrombotic therapy? Front Cardiovasc Med. 2019;6:44. DOI: https://doi.org/10.3389/fcvm.2019.00044
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736-47. DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.009449
Montalescot G, Redheuil A, Vincent F, Desch S, Benedictis M De, Eltchaninoff H, et al. Apixaban and valve thrombosis after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2022;15:1794-804. DOI: https://doi.org/10.1016/j.jcin.2022.07.014
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632. DOI: https://doi.org/10.1093/ejcts/ezac209
Jose J, Sulimov DS, El-Mawardy M, Sato T, Allali A, Holy EW, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:686-97. DOI: https://doi.org/10.1016/j.jcin.2017.01.045
Vahidkhah K, Javani S, Abbasi M, Azadani PN, Tandar A, Dvir D, et al. Blood stasis on transcatheter valve leaflets and implications for valve-in-valve leaflet thrombosis. Ann Thorac Surg. 2017;104:751-9. DOI: https://doi.org/10.1016/j.athoracsur.2017.02.052
Mangione FM, Jatene T, Gonçalves A, Fishbein GA, Mitchell RN, Pelletier MP, et al. Leaflet thrombosis in surgically explanted or post-mortem TAVR valves. JACC Cardiovasc Imaging. 2017;10:82-5. DOI: https://doi.org/10.1016/j.jcmg.2016.11.009
Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68:2670-89. DOI: https://doi.org/10.1016/j.jacc.2016.09.958
Brown ML, Park SJ, Sundt TM, Schaff HV. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 2012;144:108-111. DOI: https://doi.org/10.1016/j.jtcvs.2011.05.032
Khan JM, Dvir D, Greenbaum AB, Babaliaros VC, Rogers T, Aldea G, et al. Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:677-89. DOI: https://doi.org/10.1016/j.jcin.2018.01.247
Plitman Mayo R, Yaakobovich H, Finkelstein A, Shadden SC, Marom G. Impact of BASILICA on the thrombogenicity potential of valve-in-valve implantations. J Biomech. 2021;118:110309. DOI: https://doi.org/10.1016/j.jbiomech.2021.110309
Eng MH, Kargoli F, Wang DD, Frisoli TM, Lee JC, Villablanca PS, et al. Short- and mid-term outcomes in percutaneous mitral valve replacement using balloon expandable valves. Catheter Cardiovasc Interv. 2021;98:1193-203. DOI: https://doi.org/10.1002/ccd.29783
McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148-57. DOI: https://doi.org/10.1016/j.jacc.2018.10.051
Abdel-Wahab M, Simonato M, Latib A, Goleski PJ, Allali A, Kaur J, et al. Clinical valve thrombosis after transcatheter aortic valve-in-valve implantation. Circ Cardiovasc Interv. 2018;11:e006730. DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006730
Eng MH, Greenbaum A, Wang DD, Wyman JD, Arjomand H, Yadav P, et al. Thrombotic valvular dysfunction with transcatheter mitral interventions for postsurgical failures. Catheter Cardiovasc Interv. 2017;90:321-8. DOI: https://doi.org/10.1002/ccd.26909
Whisenant B, Jones K, Miller D, Horton S, Miner E. Thrombosis following mitral and tricuspid valve-in-valve replacement. J Thorac Cardiovasc Surg. 2015;149:e269. DOI: https://doi.org/10.1016/j.jtcvs.2014.10.075
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
